Key takeaways
- In SURMOUNT-4, participants who switched from tirzepatide to placebo after 36 weeks regained 14% of body weight over the next 52 weeks; those who continued lost a further 5.5%, for total losses of about 25% versus about 10% from baseline.
- Regain after stopping is driven by the return of appetite and by metabolic adaptation, not by lack of willpower; it is the expected physiology of obesity as a chronic condition.
- STEP 4 showed the same pattern for semaglutide: stopping at week 20 led to regaining about two-thirds of lost weight by week 68.
- There is limited trial evidence for lower-dose or less-frequent maintenance; observational data suggest some patients maintain on reduced doses, but no randomized trial has established a maintenance protocol.
- Because most patients will stay on therapy for years, the 12-month all-in price matters more than the first-month price, and a flat price with a lock is worth more than a low introductory rate.
The trial that answers the question
SURMOUNT-4 was designed to answer one question: after a patient has lost weight on tirzepatide, what happens if they keep taking it, and what happens if they stop? Published in JAMA in January 2024, it enrolled 783 adults with obesity or overweight without diabetes and gave all of them tirzepatide, escalated to 10 or 15 mg, for 36 weeks. During that lead-in they lost an average of 20.9% of body weight. The 670 who completed the lead-in were then randomized, double-blind, to continue tirzepatide or switch to placebo for a further 52 weeks.
Those who continued lost a further 5.5% on average, for a total of about 25.3% from the original baseline. Those who switched to placebo regained 14.0% of their body weight, ending at about 9.9% below the original baseline. In other words, stopping gave back roughly two-thirds of the loss within a year, and the curve was still rising at week 88. Cardiometabolic improvements in blood pressure, lipids and glucose reversed in the placebo group as the weight came back.
The same pattern with semaglutide
STEP 4, published in 2021, ran the same design with semaglutide 2.4 mg. After a 20-week run-in during which participants lost about 10.6%, those who continued lost a further 7.9% by week 68; those switched to placebo regained 6.9%. A separate extension of STEP 1 followed participants for a year after the trial ended and found that they regained about two-thirds of the weight they had lost, with cardiometabolic markers returning toward baseline.
Two drugs, two mechanisms, the same answer. Regain after stopping is not a peculiarity of one molecule; it is the physiology of obesity.
Why the weight comes back
Weight loss by any means produces a coordinated biological response that persists for at least a year. Leptin falls, ghrelin rises, and satiety hormones including GLP-1 and peptide YY fall, so appetite increases. Resting energy expenditure falls by more than the loss of body mass predicts, a phenomenon called adaptive thermogenesis. The 2011 Sumithran study in the New England Journal of Medicine measured these changes a year after diet-induced loss and found most had not normalized. GLP-1 and GIP agonists work by overriding part of that response, principally the appetite component. When the drug stops, the override stops and the underlying drive reasserts itself. Willpower is not the variable; the trials were conducted in motivated participants receiving lifestyle counselling, and they regained anyway.
What this means for how the drugs are used
The obesity-medicine consensus, reflected in the labels and in guidance from the Endocrine Society, the Obesity Society and others, is that obesity is a chronic relapsing condition and that anti-obesity medications are long-term therapy, in the same way antihypertensives are. The trials support that framing: STEP 5 showed semaglutide maintaining 15.2% loss at two years; SURMOUNT-4 showed tirzepatide maintaining and extending loss at 88 weeks. There is no evidence that a "course" of treatment resets weight to a new baseline.
Reduced-dose and spaced maintenance
The question every patient asks next is whether they can maintain on less. The honest answer is that there is no randomized trial of a maintenance protocol. The options clinicians use are stepping down to a lower dose (for example from 15 mg to 5 or 7.5 mg of tirzepatide), extending the interval between injections (every 10 to 14 days), or a combination, while monitoring weight and stepping back up if it rises. Observational data and clinical experience suggest a minority of patients maintain on reduced regimens and a majority drift upward; the SURMOUNT-1 dose-response (15.0% at 5 mg versus 20.9% at 15 mg) implies that a lower dose sustains a smaller loss. Extending the interval has pharmacokinetic logic, since tirzepatide's five-day half-life means levels fall by roughly three-quarters over two weeks, but no trial has tested it. The providers marketing "microdose maintenance" are selling an untested protocol; the microdosing article reviews the evidence.
What does have evidence is the combination of continued medication with the behaviours that independently protect against regain: adequate protein, resistance training to preserve lean mass, regular self-weighing, and early action when weight rises by a few pounds. SURMOUNT-3 showed that tirzepatide added to intensive lifestyle intervention produced larger losses than either alone.
Planning to stop, if you must
Some patients will stop: for pregnancy, for cost, for side effects, or by choice. The trials say regain should be expected and planned for rather than treated as failure. Practical steps include continuing to the lowest effective dose rather than stopping abruptly, if a clinician agrees; establishing resistance training and protein habits before stopping, because they are easier to keep than to start; setting a weight threshold at which to restart or seek help; and, for pregnancy planning, stopping at least two months before conception as the labels require. A patient who stopped because of cost should know that a verified flat-rate compounded plan is $139 to $169 per month and that the price of restarting after regain is the same as the price of continuing.
The cost of long-term therapy
If the realistic horizon is years, the relevant price is the all-in monthly cost at the maintenance dose, sustained. On our verified figures, that is $139 per month on a 12-month flat-rate plan, $1,668 a year, or about $8,340 over five years, for compounded tirzepatide. At a membership-plus-dose-tier provider whose maintenance-dose cost is about $278 per month, five years is about $16,700. At brand-name self-pay prices around $449 per month for higher-dose Zepbound vials, it is about $27,000, and with insurance coverage at a $25 to $150 copay, $1,500 to $9,000. The cheapest tirzepatide ranking is built on 12-month totals precisely because the first month is the least important one, and a provider's stated price lock, which only NexLife among ranked providers offers, is worth more over five years than a low introductory rate.
The limits of the evidence
SURMOUNT-4 followed participants for 52 weeks after stopping; regain had not plateaued. We do not know where it settles at three or five years, although the STEP 1 extension and older bariatric and dietary data suggest most patients return close to baseline within two to three years. We do not know whether repeated cycles of loss and regain carry risks of their own, although weight cycling has been associated with adverse cardiometabolic effects in observational studies. And we do not have randomized evidence for any maintenance protocol short of continued full-dose therapy. Patients deserve those uncertainties stated plainly, because the alternative, presenting these drugs as a temporary fix, leads to the discouragement that the trials predict.
Frequently asked questions
Do you regain weight after stopping tirzepatide?
Most people regain a substantial share. In SURMOUNT-4, participants who stopped after 36 weeks regained 14% of body weight over the following year, about two-thirds of what they had lost, while participants who continued lost 5.5% more.
How long do you need to stay on tirzepatide?
The trials treat obesity as a chronic condition requiring ongoing therapy, and the labels do not specify a stopping point. Most patients who want to maintain their loss stay on the medication indefinitely, at the lowest dose that holds their weight, with a clinician reviewing periodically.
Can you taper off tirzepatide slowly?
There is no randomized trial showing that tapering prevents regain. Some clinicians reduce dose or extend the interval between doses and monitor; observational reports suggest a minority of patients maintain. Any plan to stop should include a maintenance strategy agreed with a clinician.
Sources
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA 2021;325(14):1414-1425.
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011;365:1597-1604.
- Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-2091.
Citations are to primary sources (peer-reviewed trials, FDA labeling and announcements, and provider pricing pages). See our sources policy and corrections log.